UBS Group’s Aprea Therapeutics APRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $13 | Buy |
8
+5
| +167% | +$8 | ﹤0.01% | 8811 |
|
|
2025
Q1 | $6 | Sell |
3
-5,932
| -100% | -$11.9K | ﹤0.01% | 8815 |
|
|
2024
Q4 | $19.5K | Buy |
5,935
+5,932
| +197,733% | +$19.5K | ﹤0.01% | 6655 |
|
|
2024
Q3 | $8 | Hold |
3
| – | – | ﹤0.01% | 8150 |
|
|
2024
Q2 | $12 | Hold |
3
| – | – | ﹤0.01% | 8171 |
|
|
2024
Q1 | $20 | Hold |
3
| – | – | ﹤0.01% | 7860 |
|
|
2023
Q4 | $14 | Hold |
3
| – | – | ﹤0.01% | 7882 |
|
|
2023
Q3 | $13 | Hold |
3
| – | – | ﹤0.01% | 8033 |
|
|
2023
Q2 | $9 | Sell |
3
-671
| -100% | -$2.01K | ﹤0.01% | 7655 |
|
|
2023
Q1 | $2.99K | Sell |
674
-613
| -48% | -$2.72K | ﹤0.01% | 7303 |
|
|
2022
Q4 | $8.49K | Buy |
1,287
+990
| +333% | +$6.53K | ﹤0.01% | 7576 |
|
|
2022
Q3 | $4K | Sell |
297
-220
| -43% | -$2.96K | ﹤0.01% | 8219 |
|
|
2022
Q2 | $8K | Buy |
517
+254
| +97% | +$3.93K | ﹤0.01% | 7239 |
|
|
2022
Q1 | $10K | Buy |
263
+259
| +6,475% | +$9.85K | ﹤0.01% | 7337 |
|
|
2021
Q4 | $0 | Buy |
+4
| New | – | ﹤0.01% | 9092 |
|
|
2021
Q3 | – | Sell |
-66
| Closed | -$6K | – | 8328 |
|
|
2021
Q2 | $6K | Sell |
66
-58
| -47% | -$5.27K | ﹤0.01% | 7317 |
|
|
2021
Q1 | $13K | Buy |
124
+89
| +254% | +$9.33K | ﹤0.01% | 6700 |
|
|
2020
Q4 | $3K | Buy |
35
+33
| +1,650% | +$2.83K | ﹤0.01% | 6948 |
|
|
2020
Q3 | $1K | Sell |
2
-157
| -99% | -$78.5K | ﹤0.01% | 6874 |
|
|
2020
Q2 | $123K | Sell |
159
-60
| -27% | -$46.4K | ﹤0.01% | 4327 |
|
|
2020
Q1 | $152K | Sell |
219
-89
| -29% | -$61.8K | ﹤0.01% | 4089 |
|
|
2019
Q4 | $283K | Buy |
+308
| New | +$283K | ﹤0.01% | 4350 |
|